2009, Number 2
<< Back Next >>
Rev Mex Neuroci 2009; 10 (2)
Síndromes dolorosos y toxina botulínica
Quiñones S, Quiñones G, Velez JK
Language: Spanish
References: 10
Page: 122-127
PDF size: 182.59 Kb.
Text Extraction
No abstract
REFERENCES
Foster KA. A new wrinkle on pain relief: re-engineering clostridial neurotoxins for analgesics. Drug discovery today 2005; 10: 568- 83.
Klein AW. Complications and adverse reactions with the use if botulinum toxin. Dis Mon 2002; 48: 336-56.
3 . Brin MF. Botulinum toxin: chemistry, pharmacologic, toxicity, and immunology. Muscle and Nerve 1997; 20(Suppl. 6): S146- S168.
Rosales R, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle and Nerve 1996; 19: 488-95.
Goadsby PJ. Migraine pathophisiology. Headache 2005; 45(Suppl. 1): 514-24.
Dodick DW. Syllabus American Academy of Neurology. 56 Annual Meeting 2004, p. 77-110.
Naumann M, Gronseth GS, So Y, Argoff CE, Childers MK, Dykstra DD, et al. Neurology 2008; 70: 1707-14.
Porta M. Botulinum toxic and back pain. J Neurol 2004: 251(Suppl. 1): 115-8.
Ruiz CH. Toxina botulínica tipo A en el tratamiento de la neuralgia postherpética. Neurología 2008; 23(4): 259-62.
Aoki R. The antinociceptive mechanism of action of botulinum toxin A. Presented at the American Headache Society Meeting. Seattle, Wash. June; 2002.
Full text